Erythropoiesis-stimulating agents in patients with chronic kidney disease... The ESAs currently approved in Italy are epoetin alfa, epoetin beta, epoetin theta, darbepoetin alfa, CERA and biosimilars epoetin alfa and epoetin zeta....
In-depth review 2009: a requiem for rhuepos—but should we nail down the coffin in 2010?The recombinant human erythropoietins and allied proteins (epoetin alfa, attempted copies and biosimilar variants of epoetin alfa, epoetin beta, epoetin delta, epoetin zeta, epoetin theta, epoetin omega, darbepoetin alfa, and methoxy-polyethylene glycol-epoetin beta) are among the most successful and earliest examples of biotechnologically...
Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review... Ten studies involving three different epoetin SEBs (epoetin zeta, HX575 and epoetin theta) were included....
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility...Maryland, Baltimore, MD, USA; 4Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA Abstract: Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat...
